Loading clinical trials...
Loading clinical trials...
Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.
Conditions
Interventions
Teriflunomide 14 MG
Locations
1
Sweden
MS Centre
Gothenburg, Västra Götaland County, Sweden
Start Date
October 10, 2019
Primary Completion Date
March 31, 2021
Completion Date
June 30, 2021
Last Updated
December 12, 2022
Lead Sponsor
Jan Lycke
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions